Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
Mingxiang Ye, Dian Fu, Yi Ren, Faxiang Wang, Dong Wang, Fang Zhang, Xinyi Xia, Tangfeng Lv, Mingxiang Ye, Dian Fu, Yi Ren, Faxiang Wang, Dong Wang, Fang Zhang, Xinyi Xia, Tangfeng Lv
Abstract
The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergencies. A handful pieces of literature have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. To evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. Six laboratory-confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground-glass opacities and consolidation in patients #1, #2, #3, #4, and #6. In patients #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of the virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patients #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-the-art therapy during COVID-19 pandemic crisis.
Keywords: COVID-19; SARS-CoV-2; convalescent plasma therapy.
Conflict of interest statement
The authors declare that there are no conflict of interests.
© 2020 Wiley Periodicals LLC.
Figures
References
- Gillespie TR, Leendertz FH. COVID‐19: protect great apes during human pandemics. Nature. 2020;579(7800):497.
- Jacobsen KH. Will COVID‐19 generate global preparedness? Lancet. 2020;395:1013‐1014. 10.1016/S0140-6736(20)30559-6
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054‐1062. 10.1016/S0140-6736(20)30566-3
- Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. 10.1056/NEJMoa2002032
- Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID‐19) out of Wuhan [published online ahead of print March 25, 2020]. Clin Infect Dis 2020. 10.1093/cid/ciaa242
- Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‐to‐person transmission: a study of a family cluster. Lancet. 2020;395(10223):514‐23.
- Tuite AR, Ng V, Rees E, Fisman D. Estimation of COVID‐19 outbreak size in Italy. Lancet Infect Dis. 2020;20(5):537. 10.1016/S1473-3099(20)30227-9
- Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS‐CoV‐2 compared to SARS‐CoV. Cell Mol Immunol. 2020;17(5):536–538. 10.1038/s41423-020-0385-z
- Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. 10.1016/j.cell.2020.02.052
- Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS‐CoV‐2 by full‐length human ACE2. Science. 2020;367:1444‐1448. 10.1126/science.abb2762
- Webster P. Canada and COVID‐19: learning from SARS. Lancet. 2020;395(10228):936‐937.
- Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967‐1976.
- Guan W, Liu J, Yu CCT. Findings of coronavirus disease (COVID‐19) severe pneumonia. AJR Am J Roentgenol. 2020;214(5):W85‐W86. 10.2214/AJR.20.23035
- Li M, Lei P, Zeng B, et al. Coronavirus disease (COVID‐19): spectrum of CT findings and temporal progression of the disease. Acad Radiol. 2020;27(5):603–608. 10.1016/j.acra.2020.03.003
- Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID‐19 pneumonia: a longitudinal study. Radiology. 2020:200843. 10.1148/radiol.2020200843
- Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID‐19. Lancet Respir Med. 2020;8(5):433–434. 10.1016/S2213-2600(20)30127-2
- Kalil AC. Treating COVID‐19‐off‐label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020. 10.1001/jama.2020.4742
- Liu W, Fontanet A, Zhang PH, et al. Two‐year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792‐795.
- Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676‐678.
- Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta‐analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599‐609.
- Zhang JF, Yan K, Ye HH, Lin J, Zheng JJ, Cai T. SARS‐CoV‐2 turned positive in a discharged patient with COVID‐19 arouses concern regarding the present standard for discharge. Int J Infect Dis. 2020. 10.1016/j.ijid.2020.03.007
- Yao XH, Li TY, He ZC, et al. A pathological report of three COVID‐19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49:009. 10.3760/cma.j.cn112151-20200312-00193
- Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919‐922.
- Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450‐1451.
- Hui DS. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 2018;197(6):700‐701.
Source: PubMed